Search results
Results from the WOW.Com Content Network
Clemastine, also known as meclastin, is a first-generation H1 histamine antagonist (antihistamine) with anticholinergic properties (drying) and sedative side effects. [1] Like all first-generation antihistamines, it is sedating.
Treatment in MS Phase III studies is usually two years per patient. In July 2021, the FDA gave the go-ahead for an investigational new drug application (IND) for the phase 3 ENSURE program, which will evaluate IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS).
Multiple sclerosis (MS) is an autoimmune disorder in which the immune system attacks and destroys the myelin sheath of nerve cells. It most commonly strikes people between the ages of 20 and 40.
Clemastine, an antihistamine drug, has been studied for its potential to possibly promote remyelination and myelin repair in conditions like multiple sclerosis (MS). [21] [22] Early phase II clinical trials showed promise for promoting remyelination in patients with MS, with clemastine improving nerve conduction velocity in the optic nerve.
Currently it is unknown what the primary cause of MS is; if MS is a heterogeneous disease, the lesion development process would not be unique. In particular, some PPMS patients having a special clinical course named rapidly progressive multiple sclerosis could have a special genetic cause [ 47 ] and a different development process.
Nearly 2.3 million people are estimated to be living with multiple sclerosis around the world, but when Montel Williams received his official diagnosis back in 1999, not much was known about the ...
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease , MS disrupts the nervous system's ability to transmit signals , resulting in a range of signs and symptoms , including physical, mental , and sometimes psychiatric problems.
MS-377 acts selectively at the sigma-1 receptor as an antagonist. It does not act on dopamine or serotonin receptors unlike most anti-psychotics.Tests have shown that MS-377 could displace ligand binding from the sigma-1 receptor, but did this not happen at the sigma-2, 5-HT 2 and D 2 receptors, suggesting that it is selective for the sigma-1 receptor.